|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Tissue Therapeutics , Signs 2nd cGMP Manufacturing Contract With QSV Biologics, Ltd., For Synthetic Vitronectin And Chimeric VitroGro(R)-1
8/23/2006 12:08:33 PM
QSV Biologics (QSV), Ltd. Edmonton, Canada, announced today that they have signed a 2nd contract with Tissue Therapies Limited (ASX: TIS) of Brisbane, Australia. This contract is for the cGMP manufacture of clinical quantities of synthetic Vitronectin (one of the components of the VitroGro(R) platform for accelerated wound healing) and a single protein, chimeric form of VitroGro(R), called VitroGro(R)-1. The VitroGro(R)-1 protein combines the active regions of the multiple protein components of VitroGro(R). These are some of the essential materials that Tissue Therapies will use in preclinical and clinical trials early next year. Under the agreement, QSV will be responsible for technology transfer and cGMP production in QSV's licensed manufacturing facility. Terms of the final manufacturing contract remain confidential.
|
|
|
|
|
|
|
|
|
|
|